APA (7th ed.) Citation

Schorpion, A., Shenin, M., Neubauer, R., & Derk, C. (2017). SAT0328 An open-label study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis. Annals of the rheumatic diseases, 76(Suppl 2), 896. https://doi.org/10.1136/annrheumdis-2017-eular.3932

Chicago Style (17th ed.) Citation

Schorpion, A., M. Shenin, R. Neubauer, and CT Derk. "SAT0328 An Open-label Study of Ambrisentan with Anti-fibrotic Agent Combination Therapy in the Treatment of Diffuse Systemic Sclerosis." Annals of the Rheumatic Diseases 76, no. Suppl 2 (2017): 896. https://doi.org/10.1136/annrheumdis-2017-eular.3932.

MLA (9th ed.) Citation

Schorpion, A., et al. "SAT0328 An Open-label Study of Ambrisentan with Anti-fibrotic Agent Combination Therapy in the Treatment of Diffuse Systemic Sclerosis." Annals of the Rheumatic Diseases, vol. 76, no. Suppl 2, 2017, p. 896, https://doi.org/10.1136/annrheumdis-2017-eular.3932.